Showing results (31-40 of 812) with videos related to

Sort By:
Pageof 82
Oncotarget|July 31, 2016
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathwayDaniela Massihnia, Antonio Galvano, Daniele Fanale, et al.
Oncology|December 17, 2013
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer populationVincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, Barbara Adamo, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
Epidemiologia E Prevenzione|October 27, 2015
[A population study to evaluate the efficacy of influenza vaccination, 2014-2015]Antonio Russo
Cancer|July 24, 2009
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trialBruno Vincenzi, Daniele Santini, Antonio Russo, et al.
Critical Reviews in Oncology/Hematology|September 18, 2013
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspectsGiuseppe Bronte, Christian Rolfo, Elisa Giovannetti, et al.
Therapeutic Advances in Medical Oncology|October 14, 2021
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analysesValerio Gristina, Antonio Galvano, Luisa Castellana, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Therapeutic Advances in Medical Oncology|April 26, 2019
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patientsFrancesco Passiglia, Antonio Galvano, Marta Castiglia, et al.
Critical Reviews in Oncology/Hematology|August 5, 2019
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trialsDaniele Santini, Antonio Galvano, Francesco Pantano, et al.
Pageof 82